Showing 831-840 of 5550 results for "".
Humira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaVitiligo: An Update on Treatment Options
https://practicaldermatology.com/topics/skin-of-color/vitiligo-an-update-on-treatment-options/23995/From phototherapy to immunosuppresants to topical therapies, there are a number of treatment options for vitiligo.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuLive in Las Vegas: Get Ready for DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/live-in-las-vegas-get-ready-for-derm2021/19968/The DERM2021 NP/PA CME Conference offers dermatology physician assistants and nurse practitioners an opportunity to stay up to date on the latest products, drugs, and treatments in dermatology to improve care for patients. Joe Gorelick, MSN, FNP-BC, DEF President, says this year’s conference is goinNew Advancements in Microneedle Resurfacing
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-advancements-in-microneedle-resurfacing/21354/Microneedle resurfacing has quickly become one of the most in-demand aesthetic procedures, likely due to its strong results, quick healing times, and cost-effectiveness.Why Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.Humphries to Valeant, Restylane Line Expands, 2016 Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-humphries-to-valeant-restylane-line-expands-2016-highlights/18709/The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needsStep Up Your Approach to Fungal Infections
https://practicaldermatology.com/topics/general-topics/PD0709_03-php/22798/From choosing and using topical therapies to targeting onychomycosis, here are pointers for management of fungal diseases.Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/series/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.